Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 9/20 | 0.69 |
| ▸ | KCNQ2 | O43526 | 9/20 | 0.69 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3695823 | 0.81 | KCNQ3 (0.73) | KCNQ3KCNQ2LMNA | |
| SCHEMBL3707506 | 0.80 | KCNQ3 (0.84) | KCNQ3KCNQ2 | |
| SCHEMBL3707082 | 0.80 | KCNQ3 (1.00) | KCNQ3KCNQ2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3700639 | 0.79 | KCNQ3 (0.98) | KCNQ3KCNQ2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3697384 | 0.79 | KCNQ3 (0.77) | KCNQ3KCNQ2 | |
| SCHEMBL3702411 | 0.79 | KCNQ3 (0.78) | KCNQ3KCNQ2 | |
| SCHEMBL3706572 | 0.78 | KCNQ3 (0.74) | KCNQ3KCNQ2 | |
| SCHEMBL3712494 | 0.77 | KCNQ3 (0.81) | KCNQ3KCNQ2 | |
| SCHEMBL3710535 | 0.73 | KCNQ3 (0.64) | KCNQ3KCNQ2LMNASMN1; SMN2MEN1 | |
| SCHEMBL3709247 | 0.73 | KCNQ3 (0.87) | KCNQ3KCNQ2SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609669-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2013-12-17 | — | — | US | claimed |
| WO-2012067822-A1 | PYRAZOLO [1, 5 -A] PYRIMIDIN POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | claimed |
| US-20120122888-A1 | Potassium Channel Modulators | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | claimed |
| US-8609669-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| WO-2012067822-A1 | PYRAZOLO [1, 5 -A] PYRIMIDIN POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122888-A1 | Potassium Channel Modulators | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122888-A1 | Potassium Channel Modulators | KCNQ1, KCNQ2, KCNJ2 | KCNQ3 4/4885KCNQ2 2/4885P2RX7 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.